ClinicalTrials.gg
TerminatedNCT05813314Updated Oct 12, 2023

Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants

A Phase 1 interventional study of BMN 111 administration via Injector Pen and BMN 111 administration via vial and syringe in Achondroplasia, sponsored by BioMarin Pharmaceutical. Terminated at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-12.

Sponsored by BioMarin Pharmaceutical · Phase 1, Interventional, and Treatment

Why this study was terminated
The BMN 111-104 study has terminated as further optimization of the approach to achieve bio equivalence is required. The study termination was not due to any patient safety concerns.

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Achondroplasia by BioMarin Pharmaceutical — 2 open to participants now, 6 under way, 2 of them phase 3. Achondroplasia · BioMarin Pharmaceutical.

Enrollment
7th of 10
36 · median 74
Started
2023
with 1 other
Phase 1
2 of 14
none open now
Registered
12th of 14
by date

Among the 14 studies in Achondroplasia by BioMarin Pharmaceutical, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 1, and was the 12th registered.

Achondroplasia

47 studies on the registry are indexed under Achondroplasia; 13 are open to participants now.

Browse Achondroplasia studies →

Open to participants now

2 of the 14 studies in Achondroplasia by BioMarin Pharmaceutical are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 9 Achondroplasia studies recruiting now, 2 set no upper age limit and 7 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Achondroplasia by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

The purpose of this study is to establish the bioequivalence of a single SC dose of BMN 111 administered using a vial and syringe versus using an injector pen.

03

Conditions studied

  • Achondroplasia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be aged 18 to 55 years inclusive, at the time of signing the .
  2. Participants must be non-smoking (have never smoked, or stopped smoking > 3 months prior to dosing), and can be of any ethnicity.
  3. Participants must be healthy as determined by the absence of abnormalities identified by medical evaluation, including medical history, full physical examination, laboratory tests, cardiac monitoring, supine vital signs to include temperature, and assessment of prior and concomitant medications.
  4. Body weight ≥ 60 kg and \< 110 kg and within the range 18.0 to 32.0 kg/m2 (inclusive).
  5. Males and/or females are eligible to participate in this clinical study.
  6. use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  7. Females will not be pregnant or lactating, and females of and males will agree to use contraception.
  8. Participants must be capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF).

Exclusion criteria

Exclusion Criteria:

  1. Any condition considered to affect drug absorption (eg, conditions affecting SC administration such as reduced SC blood flow, lipohypertrophy, and significantly high/low skin temperature).
  2. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the investigator (or designee).
  3. History of significant , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator (or designee).
  4. History of migraines.
  5. Confirmed (eg, two consecutive measurements) systolic blood pressure > 140 or \< 90 mmHg, diastolic blood pressure > 90 or \< 50 mmHg, and pulse rate > 100 or \< 40 beats per minute or recurrent symptomatic hypotension (defined as episodes of low BP generally accompanied by symptoms e.g., dizziness and fainting) or recurrent symptomatic orthostatic hypotension.
  6. Positive hepatitis panel and/or positive test.
  7. Exposure to mycobacterium tuberculosis, indicative of tuberculosis infection, as confirmed by a positive QuantiFERON-TB Gold test.
  8. A positive COVID-19 test at Screening or Check-in.
  9. Taking any of the prohibited medications.
  10. Administration of a coronavirus disease 2019 (COVID-19) vaccine within 30 days prior to dosing.
  11. Use or intend to use any medications/products known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to dosing, unless deemed acceptable by the investigator (or designee).
  12. Use or intend to use any prescription medications/products other than hormone replacement therapy (HRT), oral, implantable, transdermal, injectable, or intrauterine within 7 days (or 14 days if the drug is a potential enzyme inducer), or 5 half-lives (whichever is longer), prior to dosing, unless deemed acceptable by the investigator (or designee).
  13. Use or intend to use slow release medications/products considered to still be active within 14 days prior to Check-in, unless deemed acceptable by the investigator (or designee).
  14. Use or intend to use any nonprescription medications/products including vitamins, minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days, or 5 half-lives (whichever is longer), prior to dosing, unless deemed acceptable by the investigator (or designee).
  15. Participation in a clinical study involving administration of an drug (new chemical entity) in the past 30 days or 5 half-lives prior to dosing (whichever is longer).
  16. Have previously completed or withdrawn from this study or any other study investigating BMN 111 and have previously received BMN 111.
  17. , alanine aminotransferase, or ≥ 1.5 × or estimated \< 60 mL/min/1.73m2 (Chronic Kidney Disease Epidemiology Collaboration 2021).
  18. Receipt of blood products within 2 months prior to Check-in.
  19. Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to Screening, or from 6 weeks prior to Screening.
  20. Poor peripheral venous access.
  21. Participants who, in the opinion of the investigator (or designee), should not participate in this study.
  22. Any skin condition, such as scarring or tattoos, which may preclude receipt of the study drug.
  23. Unwilling or unable to comply with scheduled visits, the treatment plan, laboratory tests and other study procedures or lifestyle guidance.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Active comparator
    BMN 111 injection with vial and syringe

    Study treatment will be provided in glass vials. Each glass vial will be labeled as required per country requirement. Pre-filled Diluent Transfer Syringes will be provided for reconstitution.

    Drug: BMN 111 administration via vial and syringe

  • Experimental
    BMN 111 injection with injector pen

    Study treatment will be provided in a prefilled injector pen containing a dual chamber drug cartridge, for reconstitution and injection, after setting of the specified dose with the 2.0 mg/mL formulation.

    Combination Product: BMN 111 administration via Injector Pen

Interventions

  • BMN 111 Injection will be given using an injector pen

  • DrugBMN 111 administration via vial and syringe

    BMN 111 Injection will be given using vial and syringe

06

What researchers measure

Primary outcomes

  1. Maximum observed drug concentration (Cmax)

    Time frame: Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose

  2. Area under the concentration versus time curve from time 0 to infinity (AUC0-∞)

    Time frame: Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose

  3. Area under the concentration versus time curve from time 0 to t, where t is the last timepoint with a measurable concentration (AUC0-t)

    Time frame: Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose

Secondary outcomes

  1. Time of Cmax (tmax)

    Time frame: Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose

  2. Time of t1/2

    Time frame: Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose

  3. Time of terminal rate constant (λZ)

    Time frame: Predose, 2, 5, 15, 30, 45, 60, and 75 minutes and 1.5, 2, 2.5, 3, 4, 6, and 8 hours postdose

  4. Incidence and severity of adverse events

    Time frame: 2 weeks

07

Study locations

1 site
  • Labcorp
    Dallas, Texas 75230, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jun 2023, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Apr 14, 2023
StartActual
Mar 15, 2023
Primary completionActual
Jun 14, 2023
CompletionActual
Jun 14, 2023
Last update
Oct 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05813314
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
Mar 15, 2023
Primary completion
Jun 14, 2023
Completion
Jun 14, 2023
Last update
Oct 12, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vosoritide

Start the discussion